-Reuters
Barclays Maintains Overweight on CyberArk Software, Lowers Price Target to $150
Barclays analyst Saket Kalia maintains CyberArk Software (NASDAQ:CYBR) with a Overweight and lowers the price target from $168 to $150.
Related Posts
Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca’s COVID-19 Vaccine
Oxford Biomedica plc (OTC:OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc’s (NASDAQ:AZN) COVID-19 vaccine beyond 2022. The new agreement represents…
Here’s How Much $1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.24% on an annualized basis producing an average annual return of 27.82%. Currently, Regeneron Pharmaceuticals has a market capitalization of $81.63 billion.